The refit model for end-stage liver disease-Na is not a better predictor of mortality than the refit model for end-stage liver disease in patients with cirrhosis and ascites

被引:4
|
作者
Kim, Jun Jae [1 ]
Kim, Jeong Han [1 ]
Koo, Ja Kyung [1 ]
Choi, Yun Jung [1 ]
Ko, Soon Young [1 ]
Choe, Won Hyeok [1 ]
Kwon, So Young [1 ]
机构
[1] Konkuk Univ, Sch Med, Digest Dis Ctr, Dept Internal Med, Seoul, South Korea
关键词
End Stage Liver Disease; Liver Cirrhosis; Ascites; Mortality; Hyponatremia;
D O I
10.3350/cmh.2014.20.1.47
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: The modification of the Model for End-Stage Liver Disease (MELD) scoring system (Refit MELD) and the modification of MELD-Na (Refit MELDNa), which optimized the MELD coefficients, were published in 2011. We aimed to validate the superiority of the Refit MELDNa over the Refit MELD for the prediction of 3-month mortality in Korean patients with cirrhosis and ascites. Methods: We reviewed the medical records of patients admitted with hepatic cirrhosis and ascites to the Konkuk University Hospital between January 2006 and December 2011. The Refit MELD and Refit MELDNa were compared using the predictive value of the 3-month mortality, as assessed by the Child-Pugh score. Results: In total, 530 patients were enrolled, 87 of whom died within 3 months. Alcohol was the most common etiology of their cirrhosis (n= 271, 51.1%), and the most common cause of death was variceal bleeding (n= 20, 23%). The areas under the receiver operating curve (AUROCs) for the Child-Pugh, Refit MELD, and Refit MELDNa scores were 0.754, 0.791, and 0.764 respectively; the corresponding values when the analysis was performed only in patients with persistent ascites (n= 115) were 0.725, 0.804, and 0.796, respectively. The significant difference found among the Child-Pugh, Refit MELD, and Refit MELDNa scores was between the Child-Pugh score and Refit MELD in patients with persistent ascites (P= 0.039). Conclusions: Refit MELD and Refit MELDNa exhibited good predictability for 3-month mortality in patients with cirrhosis and ascites. However, Refit MELDNa was not found to be a better predictor than Refit MELD, despite the known relationship between hyponatremia and mortality in cirrhotic patients with ascites.
引用
收藏
页码:47 / 55
页数:9
相关论文
共 50 条
  • [31] Mending the Model for End-Stage Liver Disease: An in-depth review of the past, present, and future portopulmonary hypertension Model for End-Stage Liver Disease exception
    DuBrock, Hilary M.
    del Valle, Kathryn T.
    Krowka, Michael J.
    LIVER TRANSPLANTATION, 2022, 28 (07) : 1224 - 1230
  • [32] Model for End-Stage Liver Disease score for predicting outcome in critically ill medical patients with liver cirrhosis
    Cavallazzi, Rodrigo
    Awe, Olatilewa O.
    Vasu, Tajender S.
    Hirani, Amyn
    Vaid, Urvashi
    Leiby, Benjamin E.
    Kraft, Walter K.
    Kane, Gregory C.
    JOURNAL OF CRITICAL CARE, 2012, 27 (04) : 424.e1 - 424.e6
  • [33] Model for end-stage liver disease combined with serum prealbumin to predict the prognosis of patients with decompensated liver cirrhosis
    Liu, Fei
    Cai, Ling Yan
    Zhong, Lan
    Chen, Chi
    Xu, Fei
    Zhao, Zhong Xin
    Chen, Xi Mei
    JOURNAL OF DIGESTIVE DISEASES, 2010, 11 (06) : 352 - 357
  • [34] Refitting the Model for End-Stage Liver Disease for the Eurotransplant Region
    Goudsmit, Ben F. J.
    Putter, Hein
    Tushuizen, Maarten E.
    Vogelaar, Serge
    Pirenne, Jacques
    Alwayn, Ian P. J.
    van Hoek, Bart
    Braat, Andries E.
    HEPATOLOGY, 2021, 74 (01) : 351 - 363
  • [35] Organ allocation for chronic liver disease: model for end-stage liver disease and beyond
    Asrani, Sumeet K.
    Kim, W. Ray
    CURRENT OPINION IN GASTROENTEROLOGY, 2010, 26 (03) : 209 - 213
  • [36] The model for end-stage liver disease (MELD) predicts survival of liver cirrhosis patients after discharge to hospice
    Antaki, Fadi
    Lukowski, Anna
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2007, 41 (04) : 412 - 415
  • [37] Application of a biochemical and clinical model to predict individual survival in patients with end-stage liver disease
    Vilar Gomez, Eduardo
    Calzadilla Bertot, Luis
    Gra Oramas, Bienvenido
    Arus Soler, Enrique
    Llanio Navarro, Raimundo
    Diaz Elias, Javier
    Villa Jimenez, Oscar
    Abreu Vazquez, Maria del Rosario
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (22) : 2768 - 2777
  • [38] Safety of regadenoson in patients with end-stage liver disease
    Wael AlJaroudi
    Fahad Iqbal
    Jayanth Koneru
    Pradeep Bhambhvani
    Jaekyeong Heo
    Ami E. Iskandrian
    Journal of Nuclear Cardiology, 2011, 18 : 90 - 95
  • [39] Palliative Care for Patients with End-Stage Liver Disease
    Larson A.M.
    Current Gastroenterology Reports, 2015, 17 (5)
  • [40] Liver Transplantation in Recipients With High Model for End-stage Liver Disease Score
    Gonzalez Martinez, S.
    Molina Raya, A.
    Becerra Massare, A.
    Muffak Granero, K.
    Villegas Herrera, T.
    Villar del Moral, J. M.
    Fundora Suarez, Y.
    TRANSPLANTATION PROCEEDINGS, 2018, 50 (02) : 595 - 597